77.3 F
New York
Sunday, October 1, 2023



Blue Note Therapeutics Receives Breakthrough Device Designation for Prescription-Only Digital Therapeutic for Acute Myeloid Leukemia

Related Articles

Younok Dumortier Shin Honored as a Woman of the Month for July 2023 by P.O.W.E.R. – Professional Organization of Women of Excellence Recognized

West Windsor, NJ, September 29, 2023 --(PR.com)-- Younok Dumortier Shin of West Windsor, New Jersey, has been honored as a Woman of the Month for...

Meals on Wheels South Florida Receives Grant from Meals on Wheels America to Address Social Isolation and Loneliness in South Florida

Plantation, FL, September 28, 2023 --(PR.com)-- Meals on Wheels South Florida has announced today that it has received a $10,000 grant from Meals on Wheels...

Press Release

Jan 6, 2022 16:00 EST

Blue Note Therapeutics, a prescription digital therapeutics company dedicated to easing the burden of cancer and improving outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for BNT200. BNT200 is a first-of-its-kind prescription-only digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) who are hospitalized for a regimen of high-intensity induction chemotherapy.

“For the thousands of patients diagnosed with AML each year, managing and coping with disease symptoms can be especially difficult,” said Areej El-Jawahri, M.D., Massachusetts General Hospital. “The advancement of innovative therapeutic options for the treatment of the associated distress that often follows a…

Read more…

Popular Articles